

## Special Issue

# Immunotherapy of Solid Tumors and New Ideas of Anti-tumor Metastasis

### Message from the Guest Editor

Immunotherapy has created new treatment ideas for the treatment of many cancers, and the quality of life of patients has also been greatly improved. Although immunotherapy has made exciting progress in the treatment of many cancers, such as the use of CAR-T cell therapy to treat tumors, the success of cancer immunotherapy in solid tumors has been limited. In order to challenge the difficulties caused by the immunosuppressive microenvironment that suppresses immune responses, inefficient transport, and heterogeneity of tumor antigens, novel methods have been developed. Research and clinical experience need to be unlocked. This Special Issue welcomes the submission of comprehensive research article or reviews.

### Guest Editor

Dr. Antonia Busse

Department of Hematology, Oncology and Cancer Immunology,  
Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 10117  
Berlin, Germany

### Deadline for manuscript submissions

closed (20 November 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/192047](https://mdpi.com/si/192047)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)